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Abstract
Background: Abalone has long been used as a valuable food source in East Asian countries. Although the
nutritional importance of abalone has been reported through in vitro and in vivo studies, there is little evidence
about the potential anti-tumor effects of abalone visceral extract. The aim of the present study is to examine anti-
tumor efficacy of abalone visceral extract and to elucidate its working mechanism.
Methods: In the present study, we used breast cancer model using BALB/c mouse-derived 4T1 mammary
carcinoma and investigated the effect of abalone visceral extract on tumor development. Inhibitory effect against
tumor metastasis was assessed by histopathology of lungs. Cox-2 productions by primary and secondary tumor
were measured by real-time RT-PCR and immunoblotting (IB). Proliferation assay based on [
3H]-thymidine
incorporation and measurement of cytokines and effector molecules by RT-PCR were used to confirm tumor
suppression efficacy of abalone visceral extract by modulating cytolytic CD8+ T cells. The cytotoxicity of CD8
+ T
cell was compared by JAM test.
Results: Oral administration of abalone visceral extract reduced tumor growth (tumor volume and weight) and
showed reduced metastasis as confirmed by decreased level of splenomegaly (spleen size and weight) and
histological analysis of the lung metastasis (gross analysis and histological staining). Reduced expression of Cox-2
(mRNA and protein) from primary tumor and metastasized lung was also detected. In addition, treatment of
abalone visceral extract increased anti-tumor activities of CD8
+ T cells by increasing the proliferation capacity and
their cytolytic activity.
Conclusions: Our results suggest that abalone visceral extract has anti-tumor effects by suppressing tumor growth
and lung metastasis through decreasing Cox-2 expression level as well as promoting proliferation and cytolytic
function of CD8
+ T cells.
Background
Abalones are medium to very large-sized edible sea
snails, marine gastropod mollusks in the family Halioti-
dae and the genus Haliotis [1]. Abalones are largely cul-
tivated and used as valuable food resources in East
Asian countries. In Korea, not only the protein-rich
body part of abalone but also the viscera portion is
taken in the form of sashimi or pickle and used as sta-
mina food from ancient times. Although the nutritional
composition of abalone visceral extract have not yet
been identified in depth, since abalone live on brown
algae like Ecklonia, Laminaria and Undaria for cultiva-
tion [2], it is regarded that the visceral portion of aba-
lone may contain concentrated nutritional components
derived from sea weed. Besides, it is well known that
polysaccharides and glycoproteins of the brown algae
possess potential immune-stimulant, anti-tumoral and
anti-viral activity [3]. However, there is still not much
information about the nutritional effects of abalone vis-
cera itself.
There are some previous reports that the body and
visceral portion of Haliotis discus hannai showed
in vitro antioxidant activity [4,5]. Antioxidants are
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any medium, provided the original work is properly cited.present in abundance in the dietary substances and their
potent chemopreventive effects against many type of
cancers have been reported [6]. The water extract of
abalone has anti-tumor effects [7]. However, mechan-
isms involved in the anti-tumor effects of extract from
abalone viscera have not been fully clarified. The pur-
pose of this study is to evaluate the anti-tumor activity
of abalone visceral extract in vivo using mouse breast
cancer as a model and to elucidate underlying mechan-
isms involved in this protective effect.
Breast cancer is one of the major type of cancer affect-
ing women and ranks second in causing death in women
[8]. Although many clinical trials and basic research have
been performed to subdue this disease, there is no con-
clusive treatment or medicine. Moreover, current con-
ventional chemotherapies have severe side effects and
toxicity [9,10]. Hence, there are increasing numbers of
studies to prevent cancers using dietary factors [11,12].
To evaluate the anti-tumor effects of abalone visceral
extract on breast cancer model, we used 4T1 murine
mammary carcinoma cells that have highly metastatic
characteristics at an early s t a g ea n dm i m i ct h eh u m a n
breast cancer [13,14]. Oral administration of abalone
visceral extract significantly inhibited tumor progression
by decreasing the levels of Cox-2, EGF, VEGF, and FGF
in primary tumor as well as metastatic lesions. In addi-
tion, abalone visceral extract potentiated proliferation
and cytolytic activity of CD8
+ T cells.
Methods
Animals
Balb/c mice were purchased from SLC (Hamamatsu,
Japan) and maintained under specific pathogen-free con-
ditions in the animal facility of the Gwangju Institute of
Science and Technology. Animal experiments were per-
formed in accordance with protocols approved by the
animal care and use committees of the Gwangju Insti-
tute of Science and Technology.
Preparation of the abalone visceral extract
Visceral portion of Haliotis discus hannai were obtained
from live abalone. For 500 g of abalone visceral mass,
we added 2 liters of 30% acetic acid then homogenized
thoroughly. Then, the mixture was incubated at 4°C for
12 hours with rotation. Next, the mixture was centri-
fuged at 4°C for 1 hour with 5,000 rpm. Supernatant
fraction was harvested and completely freeze-dried for
72 hours by using a freeze-dryer (Ilshin, Korea). The
dried powder extract was further finely grounded by
mortar and pestle and solubilized in sterilized PBS at 50
mg/ml concentration. Reverse phase high-performance
liquid chromatography (RP-HPLC) assay was performed
and relative amounts laminarin and D-mannitol were
used as standard makers for the quality control of
abalone visceral extract composition in each experiment
(Additional file 1: Figure S1).
Tumor induction and anti-tumor assay
Induction of breast cancer was carried out as described
[15] with minor modifications. Mice were divided into two
groups of abalone visceral extract-fed versus control PBS-
fed. Sex- and age-matched mice with similar body weight
were fed with either abalone visceral extract (5 mg/dose)
or control PBS every day for 2 weeks prior to tumor trans-
plantation. 1 × 10
6 cells/0.1 ml of 4T1 mouse mammary
carcinoma cells were injected into a subcutaneous space
on the flank of each mouse (female Balb/c mice from 6 to
8 weeks). Tumor size was measured with a Vernier caliper
every 2 days from post-tumor induction, and tumor
volumes were measured by the standard formula: width
2 ×
length × 0.52. Mice were sacrificed for further analysis at
the 25 days from post-tumor induction.
Cell isolation and culture
CD8
+ T cells were purified from the draining lymph
nodes using CD8
+ T cell isolation kit (Miltenyi Biotech,
Germany). For the activation, CD8
+ T cells were stimu-
lated with 10 μg/ml plate-bound anti-CD3, 10 μg/ml
soluble anti-CD28 in RPMI 1640 medium (Welgene,
Korea) supplemented with 10% fetal bovine serum, L-
glutamine, penicillin-streptomycin, nonessential amino
acids, sodium pyruvate, vitamins, HEPES and b-mercap-
toethanol. Anti-CD3 (145.2C11) and anti-CD28 (37.51)
were purchased from BD Biosciences.
Histopathology
Lung tissues of mice in each group were dissected and
fixed in 4% formaldehyde. After embedding in paraffin,
the tissue sections (5 μm) were mounted on glass slides
and stained with hematoxylin and eosin following the
previous report [15]. The specimens were observed
under a light microscope (Olympus, Germany).
RNA Isolation, cDNA synthesis, quantitative RT-PCR
Total RNA was extracted from the cells using TRIzol
reagent (Molecular Research Center, USA) according to
the manufacturer’s protocol. For reverse transcription,
cDNA was generated using 1 μg of total RNA, oligo(dT)
primer (Promega) and Improm-II Reverse Transcriptase
(Promega) in a total volume of 20 μl. One microliter of
cDNA was amplified using the specific primers (Table. 1).
Mouse hypoxanthine-guanine phosphoribosyl transferase
(HPRT) primer was used for quantitative RT-PCR to nor-
malize the amount of cDNA used for each condition.
Proliferation assay
Assessment of lymphocyte responses against anti-
CD3 and anti-CD28 stimulation was determined by
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3H]-thymidine incorporation assays. Briefly, isolated
CD8
+ lymphocytes were plated in flat-bottom 96-well
plates and cultured in the presence or absence of stimu-
lation. After 56 hours of incubation, 0.5 μCi of [
3H]-thy-
midine (NEN, USA) was added, and cells were pulse
labeled for 16 h. The degree of proliferation was pre-
sented as counts per minutes detected by scintillation
counter (Beckman, USA).
Total lysate preparation and immunoblotting
For total lysate preparation, tumor and lung tissues were
first homogenized using homogenizer (Pro Scientific,
USA) and then centrifuged briefly. Next, pelleted cells
were lysed in RIPA buffer (50 mM Tris, pH 7.6, 150
mM NaCl, 1% NP-40) containing protease inhibitor
cocktails (Roche, USA) for 10 min on ice. To determine
levels of Cox-2 proteins, total lysates from each sample
were prepared described above and loaded together with
a PageRuler Prestained Protein ladder (Fermentas,
Canada) on a 10% SDS-PAGE gel. The proteins were
electroblotted onto a nitrocellulose membrane (Bio-Rad,
USA). After blocking, the membranes were incubated
with a 1/500 dilution of anti-Cox-2 (Cayman chemical,
USA) in blocking buffer overnight at 4°C. The blots
were developed using a 1/10,000 diluted anti-rabbit
HRP (Abcam, USA) and visualized by ECL solution
(Amersham, UK). To confirm the amount of sample
loading and transfer, membranes were incubated in
stripping buffer, re-blocked for 1 h, and reprobed with
anti-b-tubulin (Santa Cruz) with anti-mouse HRP
(Abcam).
JAM test
The cytotoxicity of CD8
+ T cell was compared by JAM
test with minor modification [16]. EL4 mouse lym-
phoma cells were used as target cells. Target cells were
labeled with 5 μCi/ml of [
3H]-thymidine (NEN, USA)
for 12 hours at 37°C. Labeled target cells were har-
vested, washed 3 times with PBS, and seeded in 96-well
flat-buttom plates at a density of 1 × 10
4 cells/well.
CD8
+ T cells were used as effector cells. Activated
CD8
+ T cells were washed and added in various ratios
to the target cells. After 16 hours co-culture, remained
radioactivity from intact cells can be trapped in the filter
paper and then the filter discs were measured on a
microplate beta counter (Beckman, USA). Data were
expressed as the percentage of cytotoxicity calculated by
the following formula: [(cpm spontaneous - cpm experi-
ment)/cpm spontaneous] × 100.
Statistical analysis
All the data were expressed as mean ± standard error
(SE). For statistical analysis, two-tailed student’s t-test
was employed unless otherwise stated. Differences were
considered statistically significant with a p-value of
≤ 0.05 (* < 0.05, ** < 0.01, *** < 0.001).
Results
Administration of abalone visceral extract suppresses
tumor growth
To ensure the quality and purity of each preparation of
abalone visceral extract, RP-HPLC analysis was per-
formed by measuring the content of known active com-
pounds such as laminarin and D-mannitol which are
known as major polysaccharide constituents in Lami-
naria, the food for abalone. (Additional file 1: Figure S1).
To determine the dose of abalone visceral extract that
does not induce in vivo toxicity upon oral administration,
Balb/C mice were fed with 5 mg of abalone visceral extract
using feeding needle every other day for 20 days and the
body weight was measured (Additional file 2: Figure S2A).
Overall, mice viability and changes in body weight were
not affected by administration of abalone visceral extract.
In addition, gross analysis of the intestine did not show
any signs of inflammation both in the control (PBS) and
abalone visceral extract fed group (Additional file 2: Figure
S2B). Anti-cancer effect of abalone visceral extract
was tested in mouse breast cancer model in Balb/C as
Table 1 Primers used for RT-PCR
Genes Sense Antisense
HPRT TTATGGACAGGACTGAAAGAC GCTTTAATGTAATCCAGCAGGT
Cox-2 TGAGCAACTATTCCAAACCAGC GCACGTAGTCTTCGATCACTATC
VEGF GCACATAGAGAGAATGAGCTTCC CTCCGCTCTGAACAAGGCT
FGF ACCCACACGTCAAACTACAAC CACTCCCTTGATAGACACAACTC
EGF TTCTCACAAGGAAAGAGCATCTC CTGCTGTCCCGTTAAGGAAAAC
MMP13 CTTCTTCTTGTTGAGCTGGACTC CTGTGGAGGTCACTGTAGACT
GzmB CCACTCTCGACCCTACATGG GGCCCCCAAAGTGACATTTATT
GzmC GCAGAGGAGATAATCGGAGGC GCACGAATTTGTCTCGAACCA
FasL TCCGTGAGTTCACCAACCAAA GGGGGTTCCCTGTTAAATGGG
TNF-a CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC
IFN-g GAGCCAGATTATCTCTTTCTACC GTTGTTGACCTCAAACTTGG
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either with 5 mg of the abalone visceral extract or PBS as
a control for 2 weeks. And then breast cancer was induced
by intradermal injection of 4T1 mouse mammary carci-
noma cells. Oral administration of abalone visceral extract
continued for additional 25 days till the end of experiment.
Administration of abalone visceral extract significantly
decreased the size of tumor formation compared with
control groups in overall. Administration of abalone visc-
eral extract significantly (about 30%) reduced tumor size
Figure 1 Suppression of tumor progression by administration of abalone visceral extract. Balb/c female mice were orally administered
with abalone visceral extract (100 ul of 50 mg/ml) for 2 weeks before cancer transplantation. Mouse breast cancer model was induced by
injection of 4T1 cell (1 × 10
6 cells) into flank backs. Abalone visceral extract or PBS as control was daily treated by oral administration for 25 days
post tumor induction. (A) Picture of tumor from each group was taken. (B) During the treatment period, tumor size was measured every 2 days
and shown in graph. (C) After 25 days from post-tumor induction, mice from each group were scarified and the weight of tumor mass was
measured. Error bars indicated SE. Data are representative of five independent experiments. One (*), two (**) or three asterisks (***) indicate
p < 0.05, p < 0.01 or p < 0.001, respectively.
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1A). During the treatment periods, tumor size was mea-
sured starting from day 7 of post-induction of cancer and
till the end of experiments, 25 day of post-induction (Fig-
ure. 1B). In addition, administration of abalone visceral
extract significantly reduced tumor mass compared with
the control group (Figure. 1C). These data suggest that
oral treatment of abalone visceral extract significantly
reduced the development and progress of tumor forma-
tion in breast cancer model.
Administration of abalone visceral extract inhibits tumor
metastasis
The 4T1 breast cancer cells are one of the highly meta-
static cancer cells [14] and metastatic splenomegaly is
known as the first manifestation of metastasis in breast
cancer [17,18]. Oral administration of the abalone visc-
eral extract reduced the lymphomegaly (data not shown)
and metastatic splenomegaly as evident from the
decreased size (Figure. 2A) and weight of spleen (Figure.
2B). From these results, we hypothesized that abalone
visceral extract could suppress the metastasis of the pri-
mary tumor. Since lung is the one of the predominant
site of metastasis in breast cancer [19-21], we first com-
pared the metastatic state of lungs between the experi-
mental groups by gross examination (Figure. 2C).
Control group showed deposited secondary tumors with
various sizes (Figure. 2C, middle panel). In contrast, the
lung of abalone visceral extract fed group showed no
secondary tumors (Figure. 2C, right panel). For more
detailed examination of metastatic state of lungs from
each group, histological examination was performed by
Figure 2 Effects of abalone visceral extract on tumor metastasis. (A) The gross analysis of spleen from normal healthy, fed with abalone
visceral extract or PBS control treated group. (B) Spleen weight was measured and shown in graph. Values are means with SE, n = 5. Data are
representative of five independent experiments. One (*), two (**) or three asterisks (***) indicate p < 0.05, p < 0.01 or p < 0.001, respectively. (C)
Gross appearance of lung from each treatment was shown and compared with normal healthy lung. Arrows from control lung picture indicate
metastatic foci (middle panel). (D) H&E-stained section of lung from each group was shown. Normal lung tissue is indicated by ‘NL’. Tumor
metastases are indicated by ‘T’. Original magnifications; ×200
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Unlikely the normal alveolar structure of normal healthy
lungs (Figure. 2D, left panel), the control group showed
massive infiltration of the tumors with increased num-
bers of small lymphatic or blood vessels (Figure. 2D,
middle panel). Interestingly, lung from the abalone visc-
eral extract treated group showed normal alveolar struc-
ture similar to the normal healthy group while control
g r o u ps h o w e dd e s t r u c t e da l v e o l a r( F i g u r e .2 D ,r i g h t
panel). These data indicate that treatment of abalone
visceral extract inhibited metastatic development of
breast cancer in lung tissues.
Administration of abalone visceral extract suppress
primary tumor growth by decreasing Cox-2 expression
Elevated Cox-2 expression is associated with increased
tumor size during breast cancer progression [22], while
specific knockdown of Cox-2 directly reduced level of
PGE2 synthesis and tumor cell growth in 4T1 cells [23].
We investigated whether anti-cancer effect of abalone
visceral extract (Figure. 1 and Figure. 2) is linked with
modulation of Cox-2 expression level. Since Cox-2 is
regulated at transcriptional and post-translational levels
[24], Cox-2 transcript and protein levels were analyzed
by real-time PCR and Western blot analysis, respectively
from the tumor cells of breast cancer mice treated either
with control (PBS) or abalone visceral extract. Mice fed
with abalone visceral extract showed significantly
reduced Cox-2 mRNA (Figure. 3A) and protein (Figure.
3B) levels compared to PBS fed control group. Tumori-
genesis is often accompanied with angiogenic develop-
ment [25]. Therefore, we further investigated whether
oral administration of abalone visceral extract could also
affect expression levels of VEGF, FGF and EGF. Indeed,
abalone visceral extract tre a t e dg r o u ps h o w e ds i g n i f i -
cantly reduced mRNA level of such targets molecules in
the tumor tissues (Figure. 3C). These results suggest
that the potent anti-tumor effect of abalone visceral
e x t r a c ti sa s s o c i a t e dw i t hd o w n - r e g u l a t i o no fC o x - 2
expression level, as well as reduced transcript levels of
tumor growth related angiogenic molecules such as
VEGF, FGF and EGF in tumor tissues.
Abalone visceral extract inhibits tumor metastasis by
modulating Cox-2 expression
Cox2 plays important roles in breast cancer metastasis
to bone [26] and increased Cox-2 level was identified as
one of the markers for metastasis [27]. Therefore, we
questioned whether suppression of tumor metastasis by
oral administration of abalone visceral extract correlates
with down-regulation of Cox-2 level in metastatic tissue.
The mRNA and protein levels of Cox-2 were deter-
mined from the lung tissue isolated from each treatment
group. Indeed, administration of abalone visceral extract
significantly reduced Cox-2 levels compared to PBS fed
group both in mRNA (Figure. 4A) and protein (Figure.
4B) levels. To further check whether oral administration
of abalone visceral extract also affected expression levels
of metastasis related molecules, we analyzed the mRNA
levels of VEGF, FGF and MMP-13 [28,29]. Indeed,
administration of abalone visceral extract significantly
decreased their expression levels (Figure. 4C). Taken
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Figure 3 Effect of administration of abalone visceral extract on
the levels of Cox-2 and angiogenic markers in primary tumor.
(A) Primary tumor mass were homogenized and Cox-2 mRNA level
was measured in each group. (B) Protein level of Cox-2 was
detected using total cell lysates from each group. b-tubulin was
used as loading control. (C) Angiogenic markers of tumor growth
were measured by quantitative real-time PCR. Values are means
with SE. Data are representative of five times independent
experiments. One (*), two (**) or three asterisks (***) indicate p <
0.05, p < 0.01 or p < 0.001, respectively.
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static effect of abalone visceral extract is associated with
down-regulation of Cox-2 expression in metastatic
lesions, as well as suppression of metastatic targets
molecules such as VEGF, FGF and MMP-13.
Abalone visceral extract potentiates the CD8
+ cytotoxic
T cell activity
Chemopreventive approaches for tumor cells are often
targeting modulation of tumor environment not only by
exerting anti-tumor activity but also by regulating the
immune system [30]. Among various types of immune
cells, CD8
+ cytotoxic T cells are well known for their
anti-tumor activity by directly killing transformed cells
through the perforin-granzyme pathway and death
ligand such as Fas and tumor-necrosis factor [31]. We
tested the possibility that the anti-tumor activity of aba-
lone visceral extract may also modulate the functional
activity of CD8
+ T cells. Firstly, we performed CD8
+
T cell proliferation assay. Abalone visceral extract-fed
group showed significantly increased (~30%) prolifera-
tion capacity compared with control CD8
+ Tc e l l sf r o m
PBS-fed group (Figure. 5A). And then, the expression
levels of cytokines related with effector function of CD8
+ T cells were determined by quantitative RT-PCR.
TNF-a and IFN-g are known important mediators of
functionality of CD8
+ T cells against tumor pathogenesis
[32]. CD8
+ T cells from the abalone visceral extract-fed
groups showed significantly increased levels of IFN-g
and TNF-a (Figure. 5B). Then, we compared the mRNA
levels of genes related with cytolytic activity of CD8
+
T cells such as granzymes (gzmB and gzmC) and Fas
ligand (FasL) (Figure. 5C). CD8
+ T cells from the
extract-fed group showed increased mRNA level of the
above target genes compared with CD8
+ T cells from
the control group. Since the expression level of cytolytic
molecules is directly linked with the killing activity of
CD8
+ T cells [33], we tested the hypothesis that CD8
+
T cells from the abalone visceral extract-treated groups
exhibited an increased CTL response than those from
the control group. We performed the JAM test to test
this hypothesis. Indeed, CD8
+ T cells from the abalone
visceral extract-treated groups showed significantly
increased killing activity than that of the control group
in a dose-dependent manner (Figure. 5D). These results
indicate that abalone visceral extract potentiates the
proliferative capacity and cytolytic activity of CD8
+
T cells in tumor draining lymph nodes.
Discussion
Abalone is often called as ‘The emperor of the seashells’
in Korea and mostly consumed as stamina food for sick
and weak individuals because of its high content of pro-
teins and vitamins [5]. Abalone mainly live on sea weeds
that contain rich and concentrated nutritional compo-
nents [2]. Apart from its known nutritional importance,
there are not many studies on the effects of the abalone
visceral extract. One of the known effects of abalone
visceral extract is its antioxidant activity as demon-
strated [4,5]. However, there are still few in vivo
C
A
B
Cox-2
-tubulin
Control Abalone
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Control Abalone
R
e
l
a
t
i
v
e
 
C
o
x
-
2
 
m
R
N
A
 
l
e
v
e
l
***
0
0.2
0.4
0.6
0.8
1
1.2
1.4
VEGF FGF MMP13
R
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
Control
Abalone
*** *** ***
Figure 4 Abalone visceral extract inhibits tumor metastasis by
modulating Cox-2 and Cox-2 related tumor metastasis markers.
(A) Metastasized lung mass were homogenized and Cox-2 mRNA
level was measured in each group by quantitative real-time PCR. (B)
Protein level of Cox-2 was detected using total cell lysates from
each group. b-tubulin was used as loading control. (C) Markers of
tumor metastasis were measured by quantitative real-time PCR.
Values are means with SE. Data are representative of five times
independent experiments. One (*), two (**) or three asterisks (***)
indicate p < 0.05, p < 0.01 or p < 0.001, respectively.
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tumor effects [7]. In the present study, we have demon-
strated the potent anti-tumor efficacy of abalone visceral
extract and have elucidated its underlying mechanism
using a mouse breast cancer model that have high
malignancy in tumor growth and metastasis [13,14].
Oral administration of abalone visceral extract signifi-
cantly lowered tumor progression and metastasis by
down-regulating the tumor-associated growth factors
such as Cox-2, EGF, VEGF and FGF, while increasing
the proliferation and cytolytic activity of CD8
+ T cells.
Cyclooxygenase-2 (Cox-2) is an enzyme that catalyzes
arachidonic acid to prostaglandins. Cox-2 is predomi-
nantly expressed in synoviocytes, fibroblasts, osteoblasts,
activated endothelial cells and tumor cells [34,35]. Cox-
2 expression is induced by pro-inflammatory and
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Figure 5 Treatment of abalone visceral extract enhances the cytolytic activity of CD8
+ Tc e l l s . After 25 days of abalone visceral extract
treatment, CD8
+ T cells in tumor draining lymph nodes (axillary, superficial, brachial and linguinal lymph node) were isolated from each group.
(A) Proliferative capacity of CD8
+ T cells from each group was tested by [
3H]-thymidine incorporation assay. (B and C) The expression levels of
cytokines (TNF-a, IFN-g) and cytolytic molecules such as granzyme B (GzmB), granzyme C (Gzmc) and FasL) were measured by quantitative real-
time PCR. The mRNA expression levels in each group were normalized with HPRT (house-keeping gene) and then fold induction of each target
gene was compared to PBS groups (expression level of control group: 1). (D) The cytotoxicity of CD8
+ T cells was compared by JAM test. CD8
+ T
cells were co-cultured with [
3H]-thymidine labeled EL4 T cells for 12 hours and the radioactivity in each sample was measured. Values are means
with SE. One (*), two (**) or three asterisks (***) indicate p < 0.05, p < 0.01 or p < 0.001, respectively.
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VEGF) [36] and cytokines (TNF-a and IL1-b). Enhanced
expression of Cox-2 is linked with tumor progression by
inducing immune suppression as well as angiogenic and
metastatic progression [34,37,38]. Elevated Cox-2
expression is associated with increased tumor size dur-
ing breast cancer progression [22,39]. Modulation of
Cox-2 expression by specific inhibitors is regarded as
good chemopreventive approach for cancer treatment.
However, Cox-2 inhibitors affect multiple cellular path-
ways and show some side effects [34,40]. Therefore, use
of nutritive supplementation substances might be
regarded as potential cancer preventive approach
[11,12]. We have found that the oral administration of
abalone visceral extract exerted anti-tumor growth
effects by inhibiting tumor volume (up to 30%) com-
pared with control feeding group (Figure. 1). The mouse
breast tumor induced by 4T1 tumor cells mimics
human breast cancer in the aspect of spontaneous
metastasis to lung, lymph nodes, liver and bone [41].
Cox-2 expression has been identified as the marker for
selective lung metastasis [27] in breast cancer model
[20]. In this study, we used 4T1 mammary adenocarci-
noma cells for tumor implantation. Oral administration
of abalone visceral extract significantly inhibited tumor
metastasis by modulating Cox-2 expression (Figure. 4).
In accordance with our result, a previous study also
demonstrated that treatment of either non-selective Cox
inhibitor or selective Cox-2 inhibitor significantly
reduced primary tumor growth and metastasis of 4T1
breast cancer cells[42]. Even though reduction of Cox-2
expression does not exactly match with inhibition of
Cox-2 activity by known inhibitors, specific knockdown
of Cox-2 directly could reduce level of PGE2 synthesis
in 4T1 cells [23]. In line with aforementioned reports,
we investigated whether abalone visceral extract changes
Cox-2 expression upon treatment. Oral administration
of abalone visceral extract reduced the metastatic sple-
nomegaly (Figure. 2A and 2B) [17,18] and lymphome-
galy (data not shown) [43]. Metastatic breast cancer has
as t r o n gt e n d e n c yt op r o p a g a t ei n t ol u n ga n db o n e
[19-21,26]. Treatment of abalone visceral extract signifi-
cantly inhibited lung metastasis (Figure. 2C and 2D) by
decreasing Cox-2 expression level (Figure. 4A and 4B).
Numerous evidences show that decreased level of Cox-2
is well correlated with metastatic inhibition from variety
kinds of cancers [44]. Furthermore, previous data sug-
gested that Cox-2 expression is associated with angio-
genesis, lymph node metastasis, and apoptosis in human
breast cancer [43] along with enhanced MMP-13
expression [28]. Interestingly, the expression levels of
VEGF, EGF and MMP-13 are all decreased upon aba-
lone visceral extract treatment (Figure. 4C). Collectively,
oral administration of abalone visceral extract reduced
metastatic progression by lowering Cox-2 expression
and other target molecules including angiogenic factors
and metalloproteinases in the metastatic tissues.
The tumor microenvironment induces active immune
tolerance and escapes immune surveillance. Boosting
the immune response can be one of the indirect ways to
eliminate or suppress tumor growth via regulating
immune homeostasis [30]. CD8
+ T cells are known to
have anti-tumor activity by killing the tumor antigens in
an antigen specific or antigen non-specific way [44,45].
Tumor specific CD8
+ T cells possess increased prolifera-
tion, cytolytic activity and induce expression of death
related proteins and cytokines [31]. However, CD8
+
T cells at tumor sites or tumor draining lymph nodes
frequently exhibit functional defects such as defective
antigen specific cytolytic activity [46], lack of perforin
expression [47], defective cytokine production and
abnormal proliferation [48,49]. Enhanced CD8
+ T cell
activity is therefore critical to eradicate tumor cells,
especially in tumor regions. In this study, oral adminis-
tration of abalone visceral extract significantly inhibited
tumor growth compared with the control (PBS-treated)
group (Figure. 1 and Figure. 2). Administration of aba-
lone visceral extract enhanced the cytolytic activity of
CD8
+ T cells by increasing the expression of effector
molecules such as cytokines (IFN-g and TNF-a)a n d
cytolytic molecules (FasL, Gzm B and Gzm C) (Figure.
5B and 5C). Even though inflammatory cytokine signal-
ing is the known stimulation for Cox-2 expression [24],
increased expression of the cytokine in CD8+ T cells
upon abalone visceral extract treatment can be
explained by other mechanisms apart from Cox-2 regu-
lation by abalone visceral extract in tumor cells. In addi-
tion, abalone visceral extract significantly increased the
specific lysis rate in the JAM test (Figure. 5D). There-
fore, the enhanced effector function of CD8
+ T cells by
administration of abalone visceral extract may enhance
anti-tumor immunity, which leads to suppression of
tumor growth and metastasis to different organs.
Conclusions
Our data suggest that abalone visceral extract suppress
primary tumor formation and inhibit tumor metastasis
by attenuating the expression of Cox-2 and other target
molecules including angiogenic factors and metallopro-
teinases. Furthermore, abalone visceral extract potentiate
immune responses of CD8
+ T cells by increasing their
proliferation and cytolytic activity. Although further stu-
dies are needed to elucidate the exact active compounds
responsible for the anti-tumor activity of abalone visc-
eral extract, our data suggest the potential use of aba-
lone visceral extract as an inhibitor of tumor growth
and metastasis by targeting Cox-2 activity and the cyto-
lytic effector function of CD8
+ T cells.
Lee et al. BMC Complementary and Alternative Medicine 2010, 10:60
http://www.biomedcentral.com/1472-6882/10/60
Page 9 of 11Additional material
Additional file 1: Supplementary Figure 1. Quantitative analysis of
Laminarin and D-mannitol in abalone visceral extract using reverse phase
high-performance liquid chromatography (RP-HPLC).
Additional file 2: Supplementary Figure 2. Toxicity test of the abalone
visceral extract upon oral administration.
List of abbreviations used
COX-2: Cyclooxygenase-2; VEGF: Vascular endothelial growth factor; FGF:
Fibroblast growth factor; EGF: Epidermal growth factor; MMP13: Matrix
metallopeptidase 13; GZMB: Granzyme B; GZMC: Granzyme C; FASL: Fas
Ligand; TNF-a: Tumor necrosis factor-alpha; IFN-g: Interferon-gamma.
Acknowledgements
This work was supported by grants from the BioGreen 21 Program
(20070501034009; PJ007054) in Rural Development Administration and an
Agricultural R&D Promotion Center, Republic of Korea, RTI05-01-01 from the
Regional Technology Innovation Program of the Ministry of Commerce,
Industry and Energy, Korea Research Foundation funded by the Korean
government (KRF-2007-313-C00507) and by the Systems Biology
Infrastructure Establishment Grant provided by Gwangju Institute of Science
and Technology.
Author details
1School of Life Sciences and Immune Synapse Research Center, Gwangju
Institute of Science and Technology (GIST), Gwangju 500-712, Republic of
Korea.
2Global leader program, Bugil Academy, Cheonan,
Chungchengnamdo 330-941, Republic of Korea.
Authors’ contributions
S-H.I and J.I.K designed the research; C-G.L, H-K.K and C-R.I conducted
research; J.H.R and S.J.K helped the HPLC experiments and analysis; C-G.L
and S-H.I analyzed data; C-G.L and S-H.I wrote the paper; S-H.I had primary
responsibility for final content. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 19 April 2010 Accepted: 20 October 2010
Published: 20 October 2010
References
1. Wikipedia contributors:[http://en.wikipedia.org/w/index.php?
title=Abalone&oldid=306576568], Abalone [Internet]. Wikipedia TFEA, [cited
2009 Aug 7].
2. Hwang E, Baek J, Park C: The mass cultivation of Ecklonia stolonifera
Okamura as a summer feed for the abalone industry in Korea. Journal of
Applied Phycology 2009.
3. Smit AJ: Medicinal and pharmaceutical uses of seaweed natural
products: A review. Journal of Applied Phycology 2004, 16(4):245-262.
4. Zhu B-W, Wang L-S, Zhou D-Y, Li D-M, Sun L-M, Yang J-F, Wu H-T, Zhou X-
Q, Tada M: Antioxidant activity of sulphated polysaccharide conjugates
from abalone (Haliotis discus hannai Ino). European Food Research and
Technology 2008, 227(6):1663-1668.
5. Kim HL, Kang SG, Kim IC, Kim SJ, Kim DW, Ma SJ, Gao T, Li H, Kim MJ,
Lee TH, et al: In vitro Anti-hypertensive, Antioxidant and Anticoagulant
Activities of Extracts from Haliotis discus hannai. Journal of The Korean
Society of Food Science and Nutrition 2006, 35(7):835-840, Korean.
6. Khan N, Afaq F, Mukhtar H: Cancer Chemoprevention Through Dietary
Antioxidants: Progress and Promise. Antioxidants & Redox Signaling 2008,
10(3):475-510.
7. Uchida H, Sasaki T, Uchida NA, Takasuka N, Endo Y, Kamiya H: Oncostatic
and immunomodulatory effects of a glycoprotein fraction from water
extract of abalone, Haliotis discus hannai. Cancer Immunology,
Immunotherapy 1987, 24(3):207-212.
8. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer
Statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96.
9. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU:
Long-term follow-up of patients with complete remission following
combination chemotherapy for metastatic breast cancer. J Clin Oncol
1996, 14(8):2197-2205.
10. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A,
Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of Chemotherapy
plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer
That Overexpresses HER2. N Engl J Med 2001, 344(11):783-792.
11. Gonzalez CA: Nutrition and cancer: the current epidemiological evidence.
British Journal of Nutrition 2006, 96(S1):S42-S45.
12. Donaldson M: Nutrition and cancer: A review of the evidence for an anti-
cancer diet. Nutrition Journal 2004, 3(1):19.
13. Huang X, Wong MK, Yi H, Watkins S, Laird AD, Wolf SF, Gorelik E:
Combined Therapy of Local and Metastatic 4T1 Breast Tumor in Mice
Using SU6668, an Inhibitor of Angiogenic Receptor Tyrosine Kinases,
and the Immunostimulator B7.2-IgG Fusion Protein. Cancer Res 2002,
62(20):5727-5735.
14. Pulaski BA, Ostrand-Rosenberg S: Reduction of Established Spontaneous
Mammary Carcinoma Metastases following Immunotherapy with Major
Histocompatibility Complex Class II and B7.1 Cell-based Tumor Vaccines.
Cancer Res 1998, 58(7):1486-1493.
15. Ho-Keun K, Won Kyung J, Ji-Sun H, Choong-Gu L, Jae-Seon S, Jin AP,
Byoung Seob K, Sin-Hyeog I: Cinnamon extract suppresses tumor
progression by modulating angiogenesis and the effector function of
CD8+ T cells. Cancer letters 2009, 278(2):174-182.
16. Usharauli D, Perez-Diez A, Matzinger P: The JAM Test and its daughter P-
JAM: simple tests of DNA fragmentation to measure cell death and
stasis. Nat Protocols 2006, 1(2):672-682.
17. Baruch K, Moshe S, Abraham K, Marianne S, Dany B, Eliezer R, David G:
Splenomegaly and solitary spleen metastasis in solid tumors. Cancer
1987, 60(1):100-102.
18. duPre SA, Hunter JKW: Murine mammary carcinoma 4T1 induces a
leukemoid reaction with splenomegaly: Association with tumor-derived
growth factors. Experimental and Molecular Pathology 2007, 82(1):12-24.
19. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T,
Murphy E, Yuan W, Wagner SN, et al: Involvement of chemokine receptors
in breast cancer metastasis. Nature 2001, 410(6824):50-56.
20. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR,
Manova-Todorova K, Massague J: Mediators of vascular remodelling co-
opted for sequential steps in lung metastasis. Nature 2007,
446(7137):765-770.
21. Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R, Anderson RL, Deng J,
Xu M, Briest S, Biragyn A: Breast Cancer Lung Metastasis Requires
Expression of Chemokine Receptor CCR4 and Regulatory T Cells. Cancer
Res 2009, 69(14):5996-6004.
22. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C,
Joensuu H, Isola J: Prognostic Significance of Elevated Cyclooxygenase-2
Expression in Breast Cancer. Cancer Res 2002, 62(3):632-635.
23. Neil JR, Johnson KM, Nemenoff RA, Schiemann WP: Cox-2 inactivates
Smad signaling and enhances EMT stimulated by TGF-beta through a
PGE2-dependent mechanisms. Carcinogenesis 2008, 29(11):2227-2235.
24. Ghosh N, Chaki R, Mandal V, Mandal SC: COX-2 as a target for cancer
chemotherapy. Pharmacol Rep 2010, 62(2):233-244.
25. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat
Rev Cancer 2003, 3(6):401-410.
26. Singh B, Berry JA, Shoher A, Ayers GD, Wei C, Lucci A: COX-2 involvement
in breast cancer metastasis to bone. Oncogene 2007, 26(26):3789-3796.
27. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB,
Gerald WL, Massague J: Genes that mediate breast cancer metastasis to
lung. Nature 2005, 436(7050):518-524.
28. Zhang B, Cao X, Liu Y, Cao W, Zhang F, Zhang S, Li H, Ning L, Fu L, Niu Y,
et al: Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates
with poor prognosis of invasive breast cancer. BMC Cancer 2008, 8(1):83.
29. Larkins T, Nowell M, Singh S, Sanford G: Inhibition of cyclooxygenase-2
decreases breast cancer cell motility, invasion and matrix
metalloproteinase expression. BMC Cancer 2006, 6(1):181.
30. Lake RA, Robinson BWS: Immunotherapy and chemotherapy - a practical
partnership. Nat Rev Cancer 2005, 5(5):397-405.
Lee et al. BMC Complementary and Alternative Medicine 2010, 10:60
http://www.biomedcentral.com/1472-6882/10/60
Page 10 of 1131. Trapani JA, Smyth MJ: Functional significance of the perforin/granzyme
cell death pathway. Nat Rev Immunol 2002, 2(10):735-747.
32. Dranoff G: Cytokines in cancer pathogenesis and cancer therapy. Nat Rev
Cancer 2004, 4(1):11-22.
33. Glimcher LH, Townsend MJ, Sullivan BM, Lord GM: Recent developments
in the transcriptional regulation of cytolytic effector cells. Nat Rev
Immunol 2004, 4(11):900-911.
34. Gasparini G, Longo R, Sarmiento R, Morabito A: Inhibitors of cyclo-
oxygenase 2: a new class of anticancer agents? The Lancet Oncology
2003, 4(10):605-615.
35. Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama J, Osada T, Saito S,
Tsuruo T, Shibata Y, Nagawa H: Cyclooxygenase-2 overexpression
correlates with tumour recurrence, especially haematogenous
metastasis, of colorectal cancer. British Journal of Cancer 2000,
83(3):324-328.
36. Schneider BP, Miller KD: Angiogenesis of Breast Cancer. J Clin Oncol 2005,
23(8):1782-1790.
37. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL:
Cyclooxygenase-2 Inhibition by Celecoxib Reduces Proliferation and
Induces Apoptosis in Angiogenic Endothelial Cells in Vivo. Cancer Res
2002, 62(3):625-631.
38. Zou W: Immunosuppressive networks in the tumour environment and
their therapeutic relevance. Nat Rev Cancer 2005, 5(4):263-274.
39. Wülfing P, Diallo R, Müller C, Wülfing C, Poremba C, Heinecke A, Rody A,
Greb RR, Böcker W, Kiesel L: Analysis of cyclooxygenase-2 expression in
human breast cancer: high throughput tissue microarray analysis.
Journal of Cancer Research and Clinical Oncology 2003, 129(7):375-382.
40. Wang D, DuBois RN: PROSTAGLANDINS AND CANCER. Gut 2006,
55(1):115-122.
41. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D,
Javni J, Miller FR, Slavin J, et al: A novel orthotopic model of breast cancer
metastasis to bone. Clinical and Experimental Metastasis 1999,
17(2):163-170.
42. Connolly EM, Harmey JH, O’Grady T, Foley D, Roche-Nagle G, Kay E,
Bouchier-Hayes DJ: Cyclo-oxygenase inhibition reduces tumour growth
and metastasis in an orthotopic model of breast cancer. Br J Cancer
2002, 87(2):231-237.
43. Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC: Cyclo-
oxygenase 2 expression is associated with angiogenesis and lymph
node metastasis in human breast cancer. J Clin Pathol 2002,
55(6):429-434.
44. Greenhough A, Smartt HJM, Moore AE, Roberts HR, Williams AC,
Paraskeva C, Kaidi A: The COX-2/PGE2 pathway: key roles in the hallmarks
of cancer and adaptation to the tumour microenvironment.
Carcinogenesis 2009, 30(3):377-386.
45. Pittet MJ: Behavior of immune players in the tumor microenvironment.
Current Opinion in Oncology 2009, 21(1):53-59.
46. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F,
Rimoldi D, Guillaume P, Meidenbauer N, Mackensen A, et al: Effector
Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A
State of Local Functional Tolerance. Cancer Res 2004, 64(8):2865-2873.
47. Radoja S, Saio M, Schaer D, Koneru M, Vukmanovic S, Frey AB: CD8+
Tumor-Infiltrating T Cells Are Deficient in Perforin-Mediated Cytolytic
Activity Due to Defective Microtubule-Organizing Center Mobilization
and Lytic Granule Exocytosis. J Immunol 2001, 167(9):5042-5051.
48. Van Den Hove LE, Van Gool SW, Van Poppel H, Baert L, Coorevits L, Van
Damme B, Ceuppens JL: Phenotype, cytokine production and cytolytic
capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in
human renal cell carcinoma. Clinical & Experimental Immunology 1997,
109(3):501-509.
49. Nakagomi H: Lack of interleukin-2 (IL-2) expression and selective
expression of IL-10 mRNA in human renal cell carcinoma. International
Journal of Cancer 1995, 63(3):366-371.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6882/10/60/prepub
doi:10.1186/1472-6882-10-60
Cite this article as: Lee et al.: Abalone visceral extract inhibit tumor
growth and metastasis by modulating Cox-2 levels and CD8+ T cell
activity. BMC Complementary and Alternative Medicine 2010 10:60.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lee et al. BMC Complementary and Alternative Medicine 2010, 10:60
http://www.biomedcentral.com/1472-6882/10/60
Page 11 of 11